Selected research
Market Structure
Global Anti-VEGF Therapy for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-VEGF Therapy for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-VEGF Therapy for Cancer include Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Sanofi, Roche, Pfizer, Novartis, Janssen Biotech, Exelixis and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Anti-VEGF Therapy for Cancer market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-VEGF Therapy for Cancer and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-VEGF Therapy for Cancer revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Anti-VEGF Therapy for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-VEGF Therapy for Cancer Segment by Company
Chia Tai Tianqing
Jiangsu Hengrui Pharmaceuticals
Sanofi
Roche
Pfizer
Novartis
Janssen Biotech
Exelixis
Eli Lilly
Eisai
Boehringer Ingelheim
Bayer
AstraZeneca
Anti-VEGF Therapy for Cancer Segment by Type
VEGF Inhibitors
VEGFR Inhibitors
Anti-VEGF Therapy for Cancer Segment by Application
Non-small Cell Lung Cancer
Cervical Cancer
Colorectal Cancer
Renal Cell Carcinoma
Medullary Thyroid Cancer
Other
Anti-VEGF Therapy for Cancer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Therapy for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Therapy for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Therapy for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Anti-VEGF Therapy for Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-VEGF Therapy for Cancer industry.
Chapter 3: Detailed analysis of Anti-VEGF Therapy for Cancer companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-VEGF Therapy for Cancerrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- VEGF Inhibitors
- VEGFR Inhibitors
Applications
- Non-small Cell Lung Cancer
- Cervical Cancer
- Colorectal Cancer
- Renal Cell Carcinoma
- Medullary Thyroid Cancer
- Other
Companies covered
- Chia Tai Tianqing
- Jiangsu Hengrui Pharmaceuticals
- Sanofi
- Roche
- Pfizer
- Novartis
- Janssen Biotech
- Exelixis
- Eli Lilly
- Eisai
- Boehringer Ingelheim
- Bayer
- AstraZeneca
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 VEGF Inhibitors
- 1.2.3 VEGFR Inhibitors
- 1.3 Market Analysis by Application
- 1.3.1 Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Non-small Cell Lung Cancer
- 1.3.3 Cervical Cancer
- 1.3.4 Colorectal Cancer
- 1.3.5 Renal Cell Carcinoma
- 1.3.6 Medullary Thyroid Cancer
- 1.3.7 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Anti-VEGF Therapy for Cancer Growth Trends by Region
- 1.5.1 Global Anti-VEGF Therapy for Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026)
- 1.5.3 Anti-VEGF Therapy for Cancer Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Anti-VEGF Therapy for Cancer Market Dynamics
- 2.1 Anti-VEGF Therapy for Cancer Industry Trends
- 2.2 Anti-VEGF Therapy for Cancer Industry Drivers
- 2.3 Anti-VEGF Therapy for Cancer Industry Opportunities and Challenges
- 2.4 Anti-VEGF Therapy for Cancer Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Anti-VEGF Therapy for Cancer Revenue by Company (2021-2026)
- 3.2 Global Anti-VEGF Therapy for Cancer Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Anti-VEGF Therapy for Cancer Key Company Head office and Area Served
- 3.4 Global Anti-VEGF Therapy for Cancer Company, Product Type & Application
- 3.5 Global Anti-VEGF Therapy for Cancer Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Anti-VEGF Therapy for Cancer Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Anti-VEGF Therapy for Cancer Players Market Share by Revenue in 2025
- 3.6.3 2025 Anti-VEGF Therapy for Cancer Tier 1, Tier 2, and Tier 3
4 Anti-VEGF Therapy for Cancer Market by Type
- 4.1 Global Anti-VEGF Therapy for Cancer Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Anti-VEGF Therapy for Cancer Market Size by Type (2021-2032)
- 4.3 Global Anti-VEGF Therapy for Cancer Market Size Share by Type (2021-2032)
5 Anti-VEGF Therapy for Cancer Market by Application
- 5.1 Global Anti-VEGF Therapy for Cancer Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Anti-VEGF Therapy for Cancer Market Size by Application (2021-2032)
- 5.3 Global Anti-VEGF Therapy for Cancer Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Chia Tai Tianqing
- 6.1.1 Chia Tai Tianqing Company Information
- 6.1.2 Chia Tai Tianqing Business Overview
- 6.1.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Portfolio
- 6.1.5 Chia Tai Tianqing Recent Developments
- 6.2 Jiangsu Hengrui Pharmaceuticals
- 6.2.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 6.2.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 6.2.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Portfolio
- 6.2.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sanofi Anti-VEGF Therapy for Cancer Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 Roche
- 6.4.1 Roche Company Information
- 6.4.2 Roche Business Overview
- 6.4.3 Roche Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Roche Anti-VEGF Therapy for Cancer Product Portfolio
- 6.4.5 Roche Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pfizer Anti-VEGF Therapy for Cancer Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Novartis
- 6.6.1 Novartis Company Information
- 6.6.2 Novartis Business Overview
- 6.6.3 Novartis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Novartis Anti-VEGF Therapy for Cancer Product Portfolio
- 6.6.5 Novartis Recent Developments
- 6.7 Janssen Biotech
- 6.7.1 Janssen Biotech Company Information
- 6.7.2 Janssen Biotech Business Overview
- 6.7.3 Janssen Biotech Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Janssen Biotech Anti-VEGF Therapy for Cancer Product Portfolio
- 6.7.5 Janssen Biotech Recent Developments
- 6.8 Exelixis
- 6.8.1 Exelixis Company Information
- 6.8.2 Exelixis Business Overview
- 6.8.3 Exelixis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Exelixis Anti-VEGF Therapy for Cancer Product Portfolio
- 6.8.5 Exelixis Recent Developments
- 6.9 Eli Lilly
- 6.9.1 Eli Lilly Company Information
- 6.9.2 Eli Lilly Business Overview
- 6.9.3 Eli Lilly Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Eli Lilly Anti-VEGF Therapy for Cancer Product Portfolio
- 6.9.5 Eli Lilly Recent Developments
- 6.10 Eisai
- 6.10.1 Eisai Company Information
- 6.10.2 Eisai Business Overview
- 6.10.3 Eisai Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Eisai Anti-VEGF Therapy for Cancer Product Portfolio
- 6.10.5 Eisai Recent Developments
- 6.11 Boehringer Ingelheim
- 6.11.1 Boehringer Ingelheim Company Information
- 6.11.2 Boehringer Ingelheim Business Overview
- 6.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Portfolio
- 6.11.5 Boehringer Ingelheim Recent Developments
- 6.12 Bayer
- 6.12.1 Bayer Company Information
- 6.12.2 Bayer Business Overview
- 6.12.3 Bayer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Bayer Anti-VEGF Therapy for Cancer Product Portfolio
- 6.12.5 Bayer Recent Developments
- 6.13 AstraZeneca
- 6.13.1 AstraZeneca Company Information
- 6.13.2 AstraZeneca Business Overview
- 6.13.3 AstraZeneca Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 AstraZeneca Anti-VEGF Therapy for Cancer Product Portfolio
- 6.13.5 AstraZeneca Recent Developments
7 North America
- 7.1 North America Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 7.2 North America Anti-VEGF Therapy for Cancer Market Size by Type
- 7.2.1 North America Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
- 7.2.2 North America Anti-VEGF Therapy for Cancer Market Size by Type (2027-2032)
- 7.2.3 North America Anti-VEGF Therapy for Cancer Market Share by Type (2021-2032)
- 7.3 North America Anti-VEGF Therapy for Cancer Market Size by Application
- 7.3.1 North America Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
- 7.3.2 North America Anti-VEGF Therapy for Cancer Market Size by Application (2027-2032)
- 7.3.3 North America Anti-VEGF Therapy for Cancer Market Share by Application (2021-2032)
- 7.4 North America Anti-VEGF Therapy for Cancer Market Size by Country
- 7.4.1 North America Anti-VEGF Therapy for Cancer Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 7.4.3 North America Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 7.4.4 North America Anti-VEGF Therapy for Cancer Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 8.2 Europe Anti-VEGF Therapy for Cancer Market Size by Type
- 8.2.1 Europe Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
- 8.2.2 Europe Anti-VEGF Therapy for Cancer Market Size by Type (2027-2032)
- 8.2.3 Europe Anti-VEGF Therapy for Cancer Market Share by Type (2021-2032)
- 8.3 Europe Anti-VEGF Therapy for Cancer Market Size by Application
- 8.3.1 Europe Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
- 8.3.2 Europe Anti-VEGF Therapy for Cancer Market Size by Application (2027-2032)
- 8.3.3 Europe Anti-VEGF Therapy for Cancer Market Share by Application (2021-2032)
- 8.4 Europe Anti-VEGF Therapy for Cancer Market Size by Country
- 8.4.1 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 8.4.3 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 8.4.4 Europe Anti-VEGF Therapy for Cancer Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 9.2 China Anti-VEGF Therapy for Cancer Market Size by Type
- 9.2.1 China Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
- 9.2.2 China Anti-VEGF Therapy for Cancer Market Size by Type (2027-2032)
- 9.2.3 China Anti-VEGF Therapy for Cancer Market Share by Type (2021-2032)
- 9.3 China Anti-VEGF Therapy for Cancer Market Size by Application
- 9.3.1 China Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
- 9.3.2 China Anti-VEGF Therapy for Cancer Market Size by Application (2027-2032)
- 9.3.3 China Anti-VEGF Therapy for Cancer Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 10.2 Asia Anti-VEGF Therapy for Cancer Market Size by Type
- 10.2.1 Asia Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
- 10.2.2 Asia Anti-VEGF Therapy for Cancer Market Size by Type (2027-2032)
- 10.2.3 Asia Anti-VEGF Therapy for Cancer Market Share by Type (2021-2032)
- 10.3 Asia Anti-VEGF Therapy for Cancer Market Size by Application
- 10.3.1 Asia Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
- 10.3.2 Asia Anti-VEGF Therapy for Cancer Market Size by Application (2027-2032)
- 10.3.3 Asia Anti-VEGF Therapy for Cancer Market Share by Application (2021-2032)
- 10.4 Asia Anti-VEGF Therapy for Cancer Market Size by Country
- 10.4.1 Asia Anti-VEGF Therapy for Cancer Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 10.4.3 Asia Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 10.4.4 Asia Anti-VEGF Therapy for Cancer Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Type
- 11.2.1 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Application
- 11.3.1 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country
- 11.4.1 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Anti-VEGF Therapy for Cancer Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst